First Header Logo Second Header Logo

Connection

Steven Feldman to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Drug Administration Schedule.
Steven Feldman
Connection Strength
2.080
Drug Administration Schedule
  1. Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Sarecycline Review. Ann Pharmacother. 2020 02; 54(2):164-170.
    View in: PubMed
    Score: 0.161
  2. Okwundu N, Cardwell L, Cline A, Richardson I, Feldman SR. Is topical treatment effective for psoriasis in patients who failed topical treatment? J Dermatolog Treat. 2021 Feb; 32(1):41-44.
    View in: PubMed
    Score: 0.158
  3. Patel NU, Gowda A, Grammenos A, Onikoyi O, Feldman SR. Six week evaluation of the potential for topical desoximetasone 0.25% spray to induce photoallergic skin reaction. J Dermatolog Treat. 2018 May; 29(3):269-271.
    View in: PubMed
    Score: 0.142
  4. Oussedik E, Cardwell LA, Patel NU, Onikoyi O, Feldman SR. An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis. JAMA Dermatol. 2017 09 01; 153(9):932-934.
    View in: PubMed
    Score: 0.140
  5. Saleem MD, Negus D, Feldman SR. Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial. J Dermatolog Treat. 2018 Feb; 29(1):32-35.
    View in: PubMed
    Score: 0.138
  6. Ahn CS, Culp L, Huang WW, Davis SA, Feldman SR. Adherence in dermatology. J Dermatolog Treat. 2017 Mar; 28(2):94-103.
    View in: PubMed
    Score: 0.128
  7. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
    View in: PubMed
    Score: 0.123
  8. West C, Narahari S, O'Neill J, Davis S, Huynh M, Clark A, Boles A, Feldman SR. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013 May 15; 19(5):18182.
    View in: PubMed
    Score: 0.104
  9. Shah A, O'Neill J, Feldman SR. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. J Drugs Dermatol. 2010 Dec; 9(12):1491-4.
    View in: PubMed
    Score: 0.088
  10. Thomas K, Yelverton CB, Yentzer BA, Balkrishnan R, Fleischer AB, Feldman SR. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009; 20(2):72-5.
    View in: PubMed
    Score: 0.077
  11. Yentzer BA, Yelverton CB, Pearce DJ, Camacho FT, Makhzoumi Z, Clark A, Boles A, Fleischer AB, Balkrishnan R, Feldman SR. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol. 2008 Oct; 59(4):577-81.
    View in: PubMed
    Score: 0.074
  12. Krejci-Manwaring J, McCarty MA, Camacho F, Manuel J, Hartle J, Fleischer A, Feldman SR. Topical tacrolimus 0.1% improves symptoms of hand dermatitis in patients treated with a prednisone taper. J Drugs Dermatol. 2008 Jul; 7(7):643-6.
    View in: PubMed
    Score: 0.074
  13. Conde JF, Kaur M, Fleischer AB, Tusa MG, Camacho F, Feldman SR. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. Cutis. 2008 May; 81(5):435-41.
    View in: PubMed
    Score: 0.073
  14. Krejci-Manwaring J, Johnson KP, McCarty MA, Carroll CL, Hartle J, Manuel J, Balkrishnan R, Fleischer A, Feldman SR. Comparison of different compliance behaviors in a clinical trial. Cutis. 2007 May; 79(5):379-81.
    View in: PubMed
    Score: 0.068
  15. Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB, Feldman SR. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol. 2007 May; 6(5):495-8.
    View in: PubMed
    Score: 0.068
  16. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006 Aug; 142(8):1000-4.
    View in: PubMed
    Score: 0.065
  17. Krejci-Manwaring J, McCarty MA, Camacho F, Carroll CL, Johnson K, Manuel J, Balkrishnan R, Hartle J, Fleischer A, Feldman SR. Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol. 2006 May; 54(5 Suppl):S235-6.
    View in: PubMed
    Score: 0.064
  18. Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series. J Dermatolog Treat. 2006; 17(2):86-9.
    View in: PubMed
    Score: 0.062
  19. Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol. 2005 Nov-Dec; 4(6):727-31.
    View in: PubMed
    Score: 0.062
  20. McCall WV, Fleischer AB, Feldman SR. Diagnostic codes associated with hypnotic medications during outpatient physician-patient encounters in the United States from 1990-1998. Sleep. 2002 Mar 15; 25(2):221-3.
    View in: PubMed
    Score: 0.048
  21. Rajabi-Estarabadi A, Hasanzadeh H, Taheri A, Feldman SR, Firooz A. The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. J Dermatolog Treat. 2018 Mar; 29(2):111-115.
    View in: PubMed
    Score: 0.035
  22. Armstrong AW, Feldman SR, Korman NJ, Meng X, Guana A, Nyirady J, Herrera V, Zhao Y. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 May; 28(3):200-205.
    View in: PubMed
    Score: 0.033
  23. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016 May; 74(5):841-50.
    View in: PubMed
    Score: 0.031
  24. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.021
  25. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan; 56(1):31.e1-15.
    View in: PubMed
    Score: 0.016
  26. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004 Aug; 51(2):212-6.
    View in: PubMed
    Score: 0.014
  27. Railan D, Wilson JK, Feldman SR, Fleischer AB. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potency. Dermatol Online J. 2002 Oct; 8(2):3.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.